| Asthma
Arnuity Ellipta vs Breo Ellipta
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Arnuity Ellipta vs Breo Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBreo Ellipta has a higher rate of injection site reactions vs Arnuity Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Breo Ellipta but not Arnuity Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Arnuity Ellipta
Breo Ellipta
At A Glance
Oral inhalation
Once daily
Inhaled corticosteroid
Oral inhalation
Once daily
ICS/LABA combination
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Asthma
Dosing
Asthma (>=12 years) 1 actuation of ARNUITY ELLIPTA 100 mcg or 200 mcg once daily by oral inhalation; starting dosage based on prior asthma therapy and disease severity; maximum 200 mcg once daily.
Asthma (5-11 years) 1 actuation of ARNUITY ELLIPTA 50 mcg once daily by oral inhalation.
Chronic Obstructive Airway Disease 1 actuation of BREO ELLIPTA 100/25 mcg once daily by oral inhalation; use a short-acting beta2-agonist for breakthrough symptoms between doses.
Asthma Adults >=18 years: 1 actuation of BREO ELLIPTA 100/25 mcg or 200/25 mcg once daily by oral inhalation; pediatric patients 12-17 years: 1 actuation of BREO ELLIPTA 100/25 mcg once daily; pediatric patients 5-11 years: 1 actuation of BREO ELLIPTA 50/25 mcg once daily; maximum dose is 1 inhalation of BREO ELLIPTA 200/25 mcg once daily.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate or any excipient
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any excipient
Adverse Reactions
Most common (>=3%) Nasopharyngitis, headache, bronchitis, upper respiratory tract infection, pharyngitis, sinusitis, oral candidiasis, oropharyngeal candidiasis, oropharyngeal pain, toothache, gastroenteritis viral
Serious Hypertension, abscess, breast cancer, traumatic limb amputation, subarachnoid hemorrhage, intervertebral disc protrusion
Postmarketing Anaphylaxis, angioedema, rash, urticaria
Most common (>=3%) nasopharyngitis, upper respiratory tract infection, oropharyngeal candidiasis, headache, back pain, pneumonia, bronchitis, sinusitis, cough, arthralgia, influenza, pharyngitis, pyrexia
Serious serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia, immunosuppression, hypercorticism, adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, growth effects, glaucoma, cataracts
Postmarketing palpitations, tachycardia, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, nervousness, paradoxical bronchospasm
Pharmacology
Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity that binds the human glucocorticoid receptor with high affinity (approximately 29.9 times that of dexamethasone), inhibiting pro-inflammatory transcription factors such as NFkB and mediators involved in asthma pathogenesis.
Breo Ellipta combines fluticasone furoate, a synthetic trifluorinated ICS that inhibits inflammation via glucocorticoid receptor activation, with vilanterol, a LABA that relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors and increasing intracellular cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Arnuity Ellipta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (11/12)
Breo Ellipta
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Arnuity Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Breo Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Arnuity Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Breo Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Arnuity Ellipta.
No savings programs available for Breo Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Arnuity ElliptaView full Arnuity Ellipta profile
Breo ElliptaView full Breo Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.